Subtle variations in Pten dose determine cancer susceptibility - Wikidata - awgldk - TriplyDB

Subtle variations in Pten dose determine cancer susceptibility

Subtle variations in Pten dose determine cancer susceptibility

http://www.wikidata.org/entity/Q35055350

about

Phosphatase of regenerating liver 2 (PRL2) is essential for placental development by down-regulating PTEN (Phosphatase and Tensin Homologue Deleted on Chromosome 10) and activating Akt protein Cancer-associated PTEN mutants act in a dominant-negative manner to suppress PTEN protein function MYBBP1A suppresses breast cancer tumorigenesis by enhancing the p53 dependent anoikis A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands Pseudogenes: pseudo-functional or key regulators in health and disease?MicroRNAs in platelet production and activation Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs A coding-independent function of gene and pseudogene mRNAs regulates tumour biology The double face of Morgana in tumorigenesis Methodological aspects of the molecular and histological study of prostate cancer: focus on PTEN Phosphoinositides: tiny lipids with giant impact on cell regulation Role of the transcription factor Bcl11b in development and lymphomagenesis Competing endogenous RNAs (ceRNAs): new entrants to the intricacies of gene regulation A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia Deubiquitylase OTUD3 regulates PTEN stability and suppresses tumorigenesis HCV infection-associated hepatocellular carcinoma in humanized mice Systems biology of cancer: entropy, disorder, and selection-driven evolution to independence, invasion and "swarm intelligence"Not so pseudo anymore: pseudogenes as therapeutic targets Identification of Salvia haenkei as gerosuppressant agent by using an integrated senescence-screening assay Meet me halfway: when genomics meets structural bioinformatics.A novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity.Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis.A neuroprotective phase precedes striatal degeneration upon nucleolar stress.PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC.Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.Allelic selection of amplicons in glioblastoma revealed by combining somatic and germline analysis.Long non-coding RNA PTENP1 functions as a ceRNA to modulate PTEN level by decoying miR-106b and miR-93 in gastric cancer PRL2/PTP4A2 phosphatase is important for hematopoietic stem cell self-renewal.Emerging roles for natural microRNA sponges.A curated database of miRNA mediated feed-forward loops involving MYC as master regulator.Variation in Uteroglobin-Related Protein 1 (UGRP1) gene is associated with allergic rhinitis in Singapore Chinese.Haploinsufficient tumor suppressor genes.Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy.Rapid estrogen signaling negatively regulates PTEN activity through phosphorylation in endometrial cancer cells.Deterministic and stochastic allele specific gene expression in single mouse blastomeres Increased prevalence of eosinophilic gastrointestinal disorders in pediatric PTEN hamartoma tumor syndromes Uncovering the role of genomic "dark matter" in human disease.Maternal metabolic perturbations elicited by high-fat diet promote Wnt-1-induced mammary tumor risk in adult female offspring via long-term effects on mammary and systemic phenotypes

P2860

Q24293081-5CCE09C3-D355-4825-BC24-A2918C7F0FDC Q24295164-4E7B5193-2832-4E89-8A2F-489368CFFCB0 Q24314897-832B79AA-90DA-469A-A5DC-43BFF35C9EB5 Q24606333-FC5AD025-18D8-4B53-BCCB-15696FFAE582 Q24613267-D514CA38-7C5F-4E8E-A20F-F3FCB45D39FE Q24622537-F5347B85-CEEC-4E82-BFD5-253F72EDD6DA Q24629589-19B360C8-4272-48C1-B464-690E78B58F9C Q24632651-EF3F9DC9-4649-4D09-B58A-FA04DE781C94 Q26783788-2AFEA66B-2C8E-48B8-A414-F6A31B37B83E Q27005677-ADBEC085-2A13-473E-96F7-95DB823A30AB Q27012953-761F4A02-B7B5-4275-8D12-A65A5905EF33 Q27014084-890A684C-641B-4088-97C8-3F6314E054AF Q27022897-9BBCF185-AB76-4E38-B4B6-31059E32DF7B Q27851995-B18B6723-9EF9-48D3-A02E-12102BF62BEF Q28075211-78361C41-A8F3-4A83-8D5E-9A852517534F Q28117749-9D36645E-3ACE-4B02-9CA0-9B133C5F9351 Q28384465-34C8FF7F-9AB3-4FAE-B5F9-619268463280 Q28391909-F89327B6-DF5B-4F73-85AF-0055B586B8D6 Q28657757-536487CA-F414-40AD-AEC4-12F8523F20AD Q28818070-DF029F4F-C195-4AAC-B8A1-022559290844 Q30400158-E7CF9AE0-5379-4C4F-8545-EC7DF9308609 Q30417988-B35F0156-EF5F-4761-807B-B9CF74A4FEA1 Q30500885-03D32F54-2DE0-4680-B2BC-0591EB2F2E11 Q30545759-9D748370-D9D5-4889-8C40-76F92588D502 Q30549660-348B475E-62F5-4087-BFCA-FFBF8AB7494D Q33610890-10DAB34B-6643-4E10-8D72-AE9B3F69E5D1 Q33677421-5259502C-F1A0-4455-BDBD-E6871976E46A Q33687066-D65E4FD0-F4A2-4AC0-A31D-E44D8AF4AA3B Q33688531-3C1A036F-533E-4F7C-AB54-18AE2E13EF6A Q33779359-1F71DE6C-C481-4316-B3DB-686A5DF6F555 Q33805820-50703D78-0123-4659-9A9A-90BAFF8CA197 Q33842005-337F3FD2-BBD7-4E85-A429-9DE0262748AC Q33848525-1A5F60B0-330E-49A4-A38F-63147E135C4D Q33864922-CF12A341-A073-44E0-93F1-FD587C664992 Q33917630-C5915BDC-A3DB-4DDD-B3DE-4DC1DD64FE75 Q33921596-121CFCE7-836A-47ED-BE30-64EC36BD076A Q33952225-F430FE87-3946-4220-9CC7-68533D3EC3DE Q34030947-135AE893-657D-4F46-857C-B1881884D042 Q34031710-4592D74F-98ED-4146-B0E8-44D5004FE7FB Q34096820-A2B64DF4-613B-41B9-BE92-E06420448502

P2860

Subtle variations in Pten dose determine cancer susceptibility

http://www.wikidata.org/entity/Q35055350

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Subtle variations in Pten dose determine cancer susceptibility

@ast

Subtle variations in Pten dose determine cancer susceptibility

@en

type

label

Subtle variations in Pten dose determine cancer susceptibility

@ast

Subtle variations in Pten dose determine cancer susceptibility

@en

prefLabel

Subtle variations in Pten dose determine cancer susceptibility

@ast

Subtle variations in Pten dose determine cancer susceptibility

@en

P1433

Q35055350-13E35EC8-0571-4738-9DF9-10C182535C45

P1476

Q35055350-E8FBB86D-6104-4878-A43C-2B98807E8440

P2093

Q35055350-1408275D-81F2-45F8-991A-615A72F34DD1

Q35055350-19AC605A-D547-45F7-8DC5-84D9BEB3FA10

Q35055350-1ACF871C-5420-4F53-8CD6-0FC5725872F8

Q35055350-1D321B90-D9B0-4137-8195-884414076F31

Q35055350-489A63F1-793D-48FD-AA68-B29B3CBCE943

Q35055350-517465FB-25AF-4EED-91EC-F4B3C9E2C5A9

Q35055350-B0BB1A9B-89B5-478D-B110-75A34F2F1E46

Q35055350-C34E7D25-A1CB-4BF5-924C-5FD7CF621BA4

Q35055350-C7220946-9DE3-4323-B890-D1556E700344

Q35055350-E129AEA0-365F-469A-9842-3210A3D248F4

P2860

Q35055350-073480A5-18EA-4933-A91B-FCCCCE0AE39E

Q35055350-07589A27-AFAA-438B-BE0D-EF001F816445

Q35055350-0C97B0B2-8D02-4777-B5CE-748B5C09BC6C

Q35055350-1073B41F-DE5C-4F55-A842-D12ECE5D0279

Q35055350-23158F61-0105-4803-A8C7-F191563378B6

Q35055350-49692295-E054-45B4-9E90-50D9CC3BD576

Q35055350-701B972C-5B17-4DEB-B303-01B1F979F109

Q35055350-83591708-A90E-405D-B482-66C84DD972E1

Q35055350-8B08897B-2727-4567-AB3E-3E37A98094AD

Q35055350-9CC68A8D-FB23-4A68-99DC-C9CC575F05AD

P2888

Q35055350-2798C6FE-1138-4B9D-A430-C82A9B6AC789

P304

Q35055350-7AB8473D-A147-4811-B5BF-8292BE795FBB

P31

Q35055350-385BE60E-93D2-4ADF-9D4F-86ACB99D609F

P356

Q35055350-ECF47CB1-B212-4975-852A-29EB9885FB19

P407

Q35055350-5A73B2E6-834C-4494-A10E-DF0F775B4CB6

P433

Q35055350-D5D43F0A-F877-4C7E-8EDD-A12063AFC938

P478

Q35055350-7057933F-E5DA-4233-9C14-FC02C1092D20

P50

Q35055350-0C6F9E74-A99C-4B84-8B8C-0D72C0027C19

Q35055350-6B2290D0-C6CC-431D-947C-F400DE8AF2A3

Q35055350-810A4122-BCB4-44F6-8764-F81AEDDA508C

P577

Q35055350-D767C87E-E424-4ABD-BD99-420A2E2089F8

P5875

Q35055350-A05FD60A-0305-4557-A48F-8BEDB98BDA8B

P6179

Q35055350-0DD03631-C17D-4126-9352-ADF7154ECC7D

P698

Q35055350-FB10CC17-64B8-40F8-8BFB-BE9B01813336

P932

Q35055350-4B5A55B2-14BD-47B4-8493-3F72CF639A84

P356

P1433

Nature Genetics

P1476

Subtle variations in Pten dose determine cancer susceptibility

@en

P2093

Ainara Egia

http://www.w3.org/2001/XMLSchema#string

Andrea Alimonti

http://www.w3.org/2001/XMLSchema#string

Andrea L Richardson

http://www.w3.org/2001/XMLSchema#string

Arkaitz Carracedo

http://www.w3.org/2001/XMLSchema#string

Caterina Nardella

http://www.w3.org/2001/XMLSchema#string

Edi Brogi

http://www.w3.org/2001/XMLSchema#string

Jiangwen Zhang

http://www.w3.org/2001/XMLSchema#string

Katia Sampieri

http://www.w3.org/2001/XMLSchema#string

Lloyd C Trotman

http://www.w3.org/2001/XMLSchema#string

William J Haveman

http://www.w3.org/2001/XMLSchema#string

P2860

Two genetic hits (more or less) to cancer

Pten dose dictates cancer progression in the prostate

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

X chromosomal abnormalities in basal-like human breast cancer

Pten is essential for embryonic development and tumour suppression

Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems

Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression

The multiple roles of PTEN in tumor suppression.

Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation

HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin.

P2888

P304

454-458

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NG.556

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P50

Leonardo Salmena

John G Clohessy

Pier Paolo Pandolfi

P577

2010-04-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43183504

http://www.w3.org/2001/XMLSchema#string

P6179

1003780289

http://www.w3.org/2001/XMLSchema#string

P698

20400965

http://www.w3.org/2001/XMLSchema#string

P932

3118559

http://www.w3.org/2001/XMLSchema#string